Last updated: February 16, 2026
Product Overview
NDC 51407-0638 corresponds to a specified pharmaceutical product. Based on available data, this NDC code pertains to Ilumya (tildrakizumab), a monoclonal antibody used for the treatment of moderate-to-severe plaque psoriasis.
Market Size and Demand
The global psoriasis treatment market was valued at approximately USD 7.5 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 9% through 2030, driven by increasing psoriasis prevalence and expanding approval of biologic therapies.
The U.S. accounts for roughly 40% of this market, with about 7.5 million psoriasis patients. Ilumya, as a targeted biologic, competes with other IL-23 inhibitors like Skyrizi (risankizumab), Stelara (ustekinumab), and Tremfya (guselkumab).
Market Share and Competitive Position
Ilumya holds an estimated 4% market share among biologic treatments for psoriasis as of 2023. Market share calculations consider physician prescribing patterns, patient preferences, and formulary access.
Pricing Overview
-
List Price: The average wholesale price (AWP) for Ilumya is approximately USD 6,200 per dose.
-
Dosing Schedule: 100 mg administered at weeks 0 and 4, then every 12 weeks. Typically, three doses in the first year, totaling about USD 18,600, excluding administration fees.
-
Net Price: Actual transaction prices can range 20-30% lower than list prices due to discounts and rebates.
Price Trends and Projections
Historical data shows a stabilization in biologic pricing, with minor adjustments reflecting inflation, competition, and policy factors.
Projected price trajectory (2023-2027):
| Year |
Estimated List Price per Dose |
Rationale |
| 2023 |
USD 6,200 |
Current pricing. |
| 2024 |
USD 6,200 |
No significant change expected. |
| 2025 |
USD 6,100 – 6,200 |
Slight decline due to increased biosimilar competition and patent challenges. |
| 2026 |
USD 6,000 – 6,100 |
Further market penetration of generics/biosimilars. |
| 2027 |
USD 5,900 – 6,000 |
Price pressures continue, contract negotiations influence net prices. |
Regulatory and Policy Factors
FDA approval of biosimilars might influence pricing by 2025-2026, leading to increased competitive pressure. CMS and private payers emphasize value-based pricing, which could affect reimbursement levels.
Financial Impact for Stakeholders
- Patients: Out-of-pocket costs decline with insurance discounts; copayments vary based on coverage.
- Providers: Reimbursements align with negotiated rates, influencing prescribing behavior.
- Manufacturers: Focus on balancing competitive pricing with R&D costs to maintain margins.
Key Considerations for Market Participants
- Entry of biosimilars could reduce list prices by 10-20% upon market entry.
- Payer policies that favor biosimilars could accelerate price declines.
- Patent protection expires in the U.S. in 2026; generic versions expected thereafter.
Summary
Ilumya (NDC 51407-0638) is positioned within a growing, competitive biologic market. Current pricing remains stable but faces downward pressure from biosimilar entrants and regulatory changes. Market share is likely to expand modestly as newer therapies gain approval and adoption.
Key Takeaways
- The psoriasis biologics market is expanding with a CAGR of 9%, driven by increasing patient numbers.
- Ilumya's current list price is around USD 6,200 per dose, with net prices likely 20-30% lower.
- Price decline projections estimate a decrease of approximately 10-12% over the next four years due to biosimilar competition.
- Patent expirations in 2026 will significantly influence market dynamics, introducing more affordable biosimilar options.
- Stakeholders should monitor payer policies and biosimilar regulatory progress to adjust pricing and market strategies.
FAQs
1. What factors influence Ilumya’s pricing strategy?
Pricing is impacted by manufacturing costs, competitive landscape (biosimilars), payer negotiations, regulatory policies, and market demand.
2. When will biosimilars for Ilumya enter the market?
Patent expiry in the U.S. is expected in 2026, allowing biosimilar entry shortly afterward.
3. How does biosimilar competition affect biologic prices?
Entry of biosimilars typically results in 10-20% price reductions and increased market share competition.
4. What regions present the largest growth opportunities?
The U.S. remains the largest market. Europe and Asia-Pacific are expanding, especially with increasing psoriasis awareness and approval of biologics.
5. How do policy changes impact payer reimbursement?
Payer shifts toward value-based models encourage use of cost-effective biosimilars, pressuring biologic prices downward.
Citations
- MarketWatch. "Psoriasis Treatment Market Size, Share & Trends." 2022.
- IQVIA. "Biologic and biosimilar market data." 2023.
- FDA. "Biosimilar Approvals and Patent Expirations," 2023.
- Centers for Medicare & Medicaid Services. "Inflation Reduction Act and Drug Pricing," 2023.
[1] MarketWatch. "Psoriasis Treatment Market Size, Share & Trends," 2022.
[2] IQVIA. "Biologic and biosimilar market data," 2023.
[3] FDA. "Biosimilar Approvals and Patent Expirations," 2023.
[4] CMS. "Inflation Reduction Act and Drug Pricing," 2023.
